Pressemeldung

12. Januar 2023

Evonik and Dr. Eckel to cooperate on phytogenics

Evonik and Dr. Eckel Animal Nutrition have entered into a partnership effective January 1, 2023.

  • New component in the Gut Health Solutions portfolio from Evonik Animal Nutrition
  • Phytogenics are important components of alternative solutions to antibiotic growth promoters
  • Product from this partnership to be available in Europe in the first quarter of 2023

Essen, Germany. Evonik and Dr. Eckel Animal Nutrition have entered into a partnership effective January 1, 2023. This agreement will enable Evonik's Animal Nutrition business line to expand its product portfolio in the Gut Health Solutions area to include the phytogenics product class. Evonik plans to launch a first product from the partnership with Dr. Eckel in Europe in the first quarter of 2023.

Phytogenics are plant-based feed ingredients which play an important role in alternative solutions to antibiotic use in livestock farming. The use of antibiotic growth promoters in animal feed has been banned in the European Union since 2006.

"It often needs complex solutions to maintain health and productivity in the barn without antibiotics," says Gaetano Blanda, head of the Animal Nutrition business line at Evonik. “In combination with our existing Gut Health Solutions, phytogenics will help farmers achieve this goal.”

Evonik Gut Health Solutions focus primarily on stabilizing the gut health of animals through probiotics such as Ecobiol®, Fecinor®, and GutCare®. The partnership with Dr. Eckel, one of the most experienced and innovative suppliers in the field of phytogenics, will allow Evonik to address further animal health issues with selected products that expand Evonik’s portfolio.

Customized System Solutions consisting of several components and delivering sustainability benefits are part of the strategic core of Evonik's life science division Nutrition & Care, which includes the Animal Nutrition business line. With its products, services and knowhow, Evonik aims to help supply a growing world population with healthy animal protein in an efficient and sustainable way.

“As a dynamic company with a high pace in product development, we are able to create innovations in a comparatively short period of time,” says Dr. Antje Eckel, founder of Dr. Eckel Animal Nutrition. “With a strong partner like Evonik, we can allow selected products to access a much wider market in a short time. We are therefore very happy that together with Evonik we can open up new target groups and customers.”

Dr. Eckel Animal Nutrition is a family-run company with international operations. A broad knowledge of plant substances and their interactions as well as experience from almost three decades of work with innovative feeding solutions allows the company to develop phytogenics with specific benefits.

Evonik: Leading beyond chemistry

Evonik geht mit der Verbindung aus Innovationsstärke und führender Technologiekompetenz über die Grenzen der Chemie hinaus. Das in mehr als 100 Ländern aktive Chemieunternehmen mit Sitz in Essen erwirtschaftete im Jahr 2024 einen Umsatz von 15,2 Milliarden € sowie ein Ergebnis (bereinigtes EBITDA) von 2,1 Milliarden €. Der gemeinsame Antrieb der rund 32.000 Mitarbeiter: mit maßgeschneiderten Produkten und Lösungen als Superkraft für die Industrie den Kunden den entscheidenden Wettbewerbsvorteil zu verschaffen - und dadurch das Leben der Menschen zu verbessern. In allen Märkten. Jeden Tag.

Rechtlicher Hinweis

Soweit wir in dieser Mitteilung Prognosen oder Erwartungen äußern oder unsere Aussagen die Zukunft betreffen, können diese Prognosen oder Erwartungen der Aussagen mit bekannten oder unbekannten Risiken und Ungewissheit verbunden sein. Die tatsächlichen Ergebnisse oder Entwicklungen können je nach Veränderung der Rahmenbedingungen abweichen. Weder Evonik Industries AG noch mit ihr verbundene Unternehmen übernehmen eine Verpflichtung, in dieser Mitteilung enthaltene Prognosen, Erwartungen oder Aussagen zu aktualisieren.